Imidazoquinoline Compounds, Pharmaceutical Compositions, and Methods

The EPO published patent EP3980415A1 for N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods of use. The patent application claims priority and covers pharmaceutical compositions containing these compounds for therapeutic applications, specifically antiviral treatments (A61P 31/12). The patent designates all EU member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.

For pharmaceutical companies developing antiviral compounds or generics, this patent establishes proprietary protection for imidazoquinoline derivatives in the EU market. Companies should conduct freedom-to-operate analyses and consider licensing negotiations with Solventum Intellectual Properties Company. IP professionals should update patent landscape assessments to account for this newly granted protection.